- 9% secured convertible bonds replace €5 million in Kreos debt
- Conversion price €2 per share
- Remaining Kreos debt facilities reduced to €1.6 million
Amsterdam, The Netherlands, October 1, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative NK-cell-based medicines for the treatment of life-threatening diseases, announces the placement of €5 million of secured convertible bonds to Kreos Capital V (UK) Limited (“Kreos”) in consideration for Kreos waiving the equivalent amount of €5 million in cash repayments under the Kreos debt facilities that the Company entered into with Kreos in 2017 and 2018. As a result of the placement of the bonds, the outstanding amount under the Kreos debt facilities has decreased to €1.6 million.